The Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung Cancer

EP. 1: Dr. Giaccone on Treatment Options in NSCLC

October 1st 2020

Giuseppe Giaccone, MD, PhD, discusses current treatment options in non–small cell lung cancer.

EP. 2: Dr. Rizvi on Biomarkers of Response to Immunotherapy in NSCLC

January 4th 2021

Naiyer A. Rizvi, MD, discusses the use of biomarkers to select patients with non–small cell lung cancer for treatment with immunotherapy.

EP. 3: Dr. West on the Use of Nivolumab/Ipilimumab in Metastatic NSCLC

January 14th 2021

Howard (Jack) West, MD, discusses the use of nivolumab in combination with ipilimumab in metastatic non–small cell lung cancer.

EP. 4: Dr. Gandara on the Benefit of Nivolumab/Ipilimumab Plus Chemo in Metastatic NSCLC

January 14th 2021

David R. Gandara, MD, discusses the benefit of nivolumab and ipilimumab in combination with chemotherapy in metastatic non–small cell lung cancer.

EP. 5: Dr. Rizvi on the Implications of the CheckMate-227 Trial With Nivolumab/Ipilimumab in NSCLC

January 26th 2021

Naiyer A. Rizvi, MD, discusses the clinical implications of the CheckMate-227 trial examining the use of nivolumab plus ipilimumab in the treatment of patients with non–small cell lung cancer.

EP. 6: Dr. Wozniak on Optimizing the Use of Immunotherapy in NSCLC

March 30th 2021

Antoinette Wozniak, MD, FACP, FASCO, discusses optimizing the use of immunotherapy in patients with non–small cell lung cancer.

EP. 7: Dr. Raez on the Impact of PD-L1 Status on Immunotherapy Outcomes in NSCLC

March 30th 2021

Luis E. Raez, MD, discusses the impact of PD-L1 status on immunotherapy outcomes for patients with non–small cell lung cancer.

EP. 8: Dr. Garon on Immunotherapy Treatment Considerations in NSCLC

April 8th 2021

Edward B. Garon, MD, discusses immunotherapy treatment considerations for patients with non–small cell lung cancer.

EP. 9: The Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung Cancer

April 15th 2021

This publication reviews the role of single-agent and dual immunotherapy for the treatment of metastatic non-small-cell lung cancer, recapping key insights from a scientific interchange & workshop.